Paper Details

  1. Home
  2. Paper Details

Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.

Author: EguchiMasamichi, IkedaSatoshi, KawanoHiroaki, KogaSeiji, KoideYuji, MaemuraKoji, MuroyaTakahiro, SatoDaisuke, TsunetoAkira, YamagataYuki, YonekuraTsuyoshi, YoshimutaTsuyoshi

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Edoxaban, an oral direct factor Xa inhibitor, is an alternative to low-molecular weight heparin for the treatment of venous thromboembolism in cancer patients.
Paper Details　
Original Abstract of the Article :
Venous thromboembolism (VTE) is a frequent and serious complication of cancer. The current guidelines in the USA and Europe recommend low-molecular weight heparin (LMWH) for the treatment of cancer-associated VTE. In Japan, LMWH is not given for the treatment of VTE; instead edoxaban, an oral direct...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jjcc.2018.03.006

データ提供：米国国立医学図書館（NLM）

Edoxaban for Venous Thromboembolism: Exploring Efficacy in Cancer Patients

Imagine a vast desert with a complex network of paths, each with its own challenges and rewards. This study delves into the realm of cancer-associated venous thromboembolism (VTE), a serious complication that can significantly impact a patient's health. The researchers sought to compare the effectiveness of edoxaban, an oral direct factor Xa inhibitor, with low-molecular weight heparin (LMWH) in treating cancer-associated VTE.

Evaluating Edoxaban's Efficacy in Cancer Patients

The study aimed to compare the effects of edoxaban with LMWH in treating VTE in patients with cancer. While LMWH is the current standard of care in the USA and Europe, edoxaban is an alternative treatment option approved in Japan. The study's findings could shed light on the efficacy and safety of edoxaban in treating cancer-associated VTE, offering valuable insights for clinicians. It's like testing different types of camels for their ability to navigate the desert, seeking the most suitable option for a specific journey.

Navigating the Complexities of Cancer-Associated VTE Treatment

This study is a critical step in understanding the effectiveness of edoxaban in treating cancer-associated VTE. It's like carefully mapping out a desert route, assessing the suitability of various paths and potential obstacles. The researchers are seeking to determine the most effective and safe treatment approach for patients with cancer who are at risk of VTE. This research could lead to improved patient outcomes and enhance the quality of care for individuals battling cancer.

Dr.Camel's Conclusion

This study highlights the importance of exploring new and effective treatment options for cancer-associated VTE, a common and potentially life-threatening complication. It is a reminder that the pursuit of better treatments is a constant journey, much like navigating a vast desert landscape. The findings of this study could lead to improved treatment strategies and enhanced patient care.

Date :
  1. Date Completed 2019-09-03
  2. Date Revised 2019-09-03
Further Info :

Pubmed ID

29661489

DOI: Digital Object Identifier

10.1016/j.jjcc.2018.03.006

Related Literature

Article Analysis
・Effects of edoxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.